The UK Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10m ($12m) in extra government funding over the next two years: targeted at helping the agency adapt post-Brexit and accelerating routes for bringing new medicines onto the...
By Mike Pears and Joel Beevers, Patent Attorneys at Potter Clarkson
January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.
In the UK alone, the numbers of employees entering the cell and gene therapy manufacturing space needs to double in the next five years, eXmoor’s MD suggested.
Preparations for an “unlikely” ‘no deal’ Brexit are underway in the UK, with the government instructing pharmaceutical companies to build their medicine reserves before March 2019.
BioIndustry Association, a trade organisation for bioindustry, has voiced its frustration at the lack of clarity facing those in the industry over Brexit.
